The European Partnership for Personalised Medicine, EP PerMed, has launched the joint transnational call 2027 (JTC2027) “Cell and Gene Therapy for Personalised Medicine” (acronym: CGT4PM2027), co-funded by the European Union, to fund multinational, innovative research projects in personalised medicine (PM), which should bring together academic, clinical/public health and private research teams, thus enhancing the competitiveness in Europe and beyond in this field. The JTC2027 will be conducted simultaneously by the participating funding organisations in their respective region/country and coordinated centrally by the Joint Call Secretariat (JCS), hosted by the French National Research Agency (ANR), France.
The JTC2027 funds research projects that aim to develop and validate innovative and novel Cell and Gene Therapies (CGT) for personalised medicine, using at least one of the following approaches:
- Somatic cell thera peutics (e.g., in the form of stem cells, organoids, or cells of the immune system),
- Gene therapeutics in the form of gene substitution, addition or suppression therapies using viral and non-viral vectors or genome editing,
- Combined cell and gene therapeutics, in the form of genetically modified cells,
- Novel biological products such as mRNA, other nucleic acid-based methods, and extracellular ves icles as vehicle for gene-based therapeutic procedure.
Accompanying the above research fields, pro posals may include:
- Diagnostic approaches to enable patient stratification or predict response, effi cacy, dosage optimisation, adverse effects or toxicity,
- Development of novel manufacturing or de livery methods provided they incorporate a personalised CGT backbone,
- Preclinical in vitro/in vivo characterisation assays for novel and personalised CGT, to assess key aspects such as batch-to-batch consistency, biodistribution, potency, stability, safety and tolerability.
An information day introducing the JTC2027 to the research community will be organised on 03 December 2026, 15:00 – 17:00 CET. Registration here.
Joint research proposals may be submitted by applicants belonging to an entity according to the following categories (subject to regional/national funding regulations; see the “Guidelines for Applicants”):
- A. Academia (research teams working in universities, other higher education institutions) or research institutes;
- B. Clinical/public health sector (research teams working in hospitals/public health and/or other healthcare settings and health organisations). Participation of clinicians (e.g. medical doctors, nurses), pharmacists and general practitioners in the research teams is encouraged;
- C. Private for-profit (enterprise) partners, e.g. SME (small and medium enterprises) and private non-profit partners, e.g. foundations, associations or non-governmental organisations.
Consortia submitting applications to this call are strongly encouraged to include partners from different categories (A, B and C)
Eligibility criteria
- Only transnational projects will be funded.
- Each consortium must involve at least three partners from three different EU Member States or Associated Countries whose funding organisations participate in the call. Each of these partners must be eligible and request funding from the respective funding organisation. All three legal entities must be independent of each other.
- The project coordinator (i.e. the principal investigator and the applicant’s organisation) must be eligible to be funded by his/her regional/national participating funding organisation. The project coordinator (i.e. principal investigator and organisation) cannot be changed between the first and second stage.
Consortium composition:
- Max. 2 project partners per consortium can request funding from the same funding organisation. For some funding organisations, the maximum number of eligible partners who can be funded in one project is limited to one (see also the “Guidelines for Applicants” for individual funding rules).
- It is mandatory to integrate at least one early-career researcher (ECR) as principal investigator in a consortium. For the EP PerMed definition of ECR, please consult section 16 (Annex III).
Pre-proposal stage:
- Maximum number of partners is 6 (no more than 2 partners from the same country, including partners on own funds),
- Maximum number of partners can be 7 if the consortium includes a 3rd partner of the same country (condition: funding requested from at least 2 different funders of the respective country; applies to only one country per consortium, including partners on own funds).
A two-step submission and evaluation procedure has been established for joint applications: preproposals and full proposals. In both phases, one joint proposal document shall be prepared by the partners of a joint transnational project. The document must be submitted to the JCS by the project coordinator by uploading it via the electronic submission system.
- Deadline for pre-proposal submission: 20 January, 2027 (14:00, CET)
- Communication of the results of the pre-proposal assessment and invitation to the full proposal stage: Expected around 9 April, 2027
- Deadline for full proposal submission: 25 May, 2027 (14:00, CEST)